Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Virus or bacteriophage
Reexamination Certificate
2011-02-22
2011-02-22
Mosher, Mary E (Department: 1648)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Virus or bacteriophage
C424S093200, C424S199100, C424S232100, C435S235100, C435S236000, C435S320100
Reexamination Certificate
active
07892533
ABSTRACT:
The invention relates inter alia to a method for inducing a long-term protection in an animal against foreign antigens and tumor antigens comprising the step of administering to the animal at least one factor selected from type I interferons and Flt-3, and to a method for inducing a long-term increase of the number of dendritic cells in an animal comprising the step of administering to the animal a factor selected from type I interferon and Flt-3 and to a method of inducing or enhancing the maturation and/or for the activation of the immune system of an animal comprising the step of administering to the animal a factor selected from type I interferon and Flt-3.
REFERENCES:
patent: 3914408 (1975-10-01), Mebus
patent: 4191745 (1980-03-01), Mayr et al.
patent: 5338683 (1994-08-01), Paoletti
patent: 5403582 (1995-04-01), Nazerian et al.
patent: 5405772 (1995-04-01), Ponting
patent: 5753489 (1998-05-01), Kistner et al.
patent: 5756341 (1998-05-01), Kistner et al.
patent: 5770212 (1998-06-01), Falkner et al.
patent: 5843456 (1998-12-01), Paoletti et al.
patent: 6190655 (2001-02-01), Lyman et al.
patent: 6204250 (2001-03-01), Bot et al.
patent: 6605465 (2003-08-01), Paoletti
patent: 6685950 (2004-02-01), Weber et al.
patent: 6761893 (2004-07-01), Chaplin
patent: 6805870 (2004-10-01), Mayr et al.
patent: 6913752 (2005-07-01), Chaplin et al.
patent: 7097842 (2006-08-01), Suter et al.
patent: 7189536 (2007-03-01), Chaplin et al.
patent: 7384644 (2008-06-01), Chaplin et al.
patent: 7445924 (2008-11-01), Chaplin et al.
patent: 7628980 (2009-12-01), Suter et al.
patent: 2005/0214323 (2005-09-01), Chaplin et al.
patent: 2005/0260156 (2005-11-01), Suter et al.
patent: 2006/0127984 (2006-06-01), Ackermann et al.
patent: 2006/0280758 (2006-12-01), Chaplin et al.
patent: 2008/0089907 (2008-04-01), Chaplin et al.
patent: 2009/0104224 (2009-04-01), Ackermann et al.
patent: 2009/0169579 (2009-07-01), Chaplin et al.
patent: 2010/0119545 (2010-05-01), Chaplin et al.
patent: 2370573 (2002-07-01), None
patent: 90/12882 (1990-11-01), None
patent: 95/22978 (1995-08-01), None
patent: 97/02355 (1997-01-01), None
patent: 97/31119 (1997-08-01), None
patent: 98/13500 (1998-04-01), None
patent: 98/17283 (1998-04-01), None
patent: 98/56919 (1998-12-01), None
patent: 99/07869 (1999-02-01), None
patent: 00/29428 (2000-05-01), None
patent: 01/68820 (2001-09-01), None
patent: 01/89559 (2001-11-01), None
patent: 01/95919 (2001-12-01), None
patent: 02/42480 (2002-05-01), None
Oxford Biomedica PLC et al., Defendants' Answer to Plaintiff's First Amended Complaint and Counterclaims, Case No. 08cv1156-MMA (RBB), Jun. 1, 2009.
Bavarian Nordic A/S, Plaintiff's Answers to Defendants' Counterclaims, Case No. 08cv1156-MMA (RBB), Jun. 22, 2009.
Bavarian Nordic A/S, Plaintiff's Motion for Partial Summary Judgement on Inequitable Conduct, Case No. 08cv1156-MMA (RBB), Jan. 25, 2010.
Declaration of Theodore J. Folkman, Case No. 08cv1156-MMA (RBB), Jan. 25, 2010.
Suter et al., Modified vaccinia Ankara strains with identical coding sequences actually represent complex mixtures of viruses that determine the biological properties of each strain, Vaccine 27:7442-7450 (2009).
Opposition Division, EPO, Opposition to EP Patent No. 1420822, EPA Form 2906, Oct. 8, 2009.
Emergent Product Development Germany GmbH, Opposition to EP Patent No. 1420822, Reply Letter, Sep. 23, 2009.
Bavarian Nordic, Opposition to EP Patent No. 1420822, Patentee Response to Oppositions, Mar. 27, 2009.
Sanofi Pasteur, Opposition to EP Patent No. 1420822, Notice of Opposition, Apr. 11, 2008.
Emergent Product Development Germany GmbH, Opposition to EP Patent No. 1420822, Notice of Opposition, Apr. 8, 2008.
Dr. Elfriede Dworak of the Commercial Court of Vienna, Austria, Decision on Initial Matter, without prejudice, in Case 19Cg 25/06g, May 31, 2007.
Mayr & Mayr, Pesq. Vet. Bras. 19:91-98 (1999).
Mayr et al., Infection 3:6-14 (1975).
Mayr et al., J. Vet Med. B. 3681-99 (1989).
Mayr et al., Drug Res. 37:988-989 (1987).
Mayr et al., J. Vet Med. B. 33:321-339 (1986).
Dr. Paul Chaplin, ITC Testimony, ITC Investigation No. 337-TA-550, 447-706, May 10, 2006.
Mayr, Swiss Vet.11:13-17 (1999).
Paul Luckern, ALJ, Order No. 5, ITC Investigation No. 337-TA-550, Jun. 29, 2007.
Bavarian Nordic, 1999 Annual Report, Mar. 14, 2000.
Bavarian Nordic, 2000 Annual Report, Mar. 6, 2001.
Oxford Biomedica (UK) Ltd, Opposition to EP Patent No. 1335987, Additional Submissions, Dec. 7, 2009.
Bavarian Nordic, Opposition to EP Patent No. 1335987, Reply to Submissions, Jun. 18, 2008.
Oxford Biomedica (UK) Ltd, Opposition to EP Patent No. 1335987, Reply to Patentee's Response, Jan. 28, 2008.
Emergent Product Development Germany GmbH, Opposition to EP Patent No. 1335987, Submission to Patentee's Observations, Mar. 12, 2008.
Bavarian Nordic, Opposition to EP Patent No. 1335987, Response to Oppositions, Aug. 1, 2007.
Emergent Product Development Germany GmbH, Opposition to EP Patent No. 1335987, Notice of Opposition, Sep. 28, 2006.
Virbac SA, Opposition to EP Patent No. 1335987, Notice of Opposition, Sep. 28, 2006.
Innogenetics NV, Opposition to EP Patent No. 1335987, Notice of Opposition, Sep. 27, 2006.
Oxford Biomedica (UK) Ltd, Opposition to EP Patent No. 1335987, Notice of Opposition, Sep. 26, 2006.
Baxter AG, Opposition to EP Patent No. 1335987, Notice of Opposition, May 15, 2006.
Sanofi Pasteur Inc, Opposition to EP Patent No. 1335987, Notice of Opposition, Sep. 26, 2006.
Acambis PLC, Opposition to EP Patent No. 1335987, Notice of Opposition, May 15, 2006.
B. Vilsmeier, Paraimmunity inducing effects of vaccinia strain MVA. (1999) Bed. Munch. Tierarztl. Wschr. 112:329-333.
A. Mayr. Paraspeziifsche Vaccinen aus Pockenviren (Paramunitatsinducer): eine neue Art von Impfstoff (1999) Azrtezeitschrift fur Naturheilverfahren 40, 8 pp. 550-557.
M. Franchini, et al., Protective T-Cell-Based Imminity Induced in Neonatal Mice by a Single Replicative Cycle of Herpes Simplex Virus. (2001) Journal of Virology 75:83-89.
K. Stittelaar. et al. Protective Immunity in Macaques Vaccinated with a Modified Vaccinia Virus Ankara-Based Measles Virus Vaccine in the Presence of Passively Acquired Antibodies. (2000) Journal of Virology 74:4236-4243.
A. Mayr Zbl. Vet. Med. B, TC marker of the attenuated vaccinia vaccide strain “MVA” in human cell cultures and protective immunization against orthopox diseases in animals. (1976) 23:417-430.
A. Bot. et al. Induction of immunological memory in baboons primed with DNA vaccine as neonates. (2001) Vaccine 19:1960-70.
C. McLean. et al. Induction of a protective immune response by mucosa{ vaccination with a DISC HSV-1 vaccine. (1996) Vaccine 14:987-92.
M. Monteil.et al. Effective priming of neonates born to immune dams against the immunogenic pseudorabies virus glycoprotein gD by replication-incompetent adenovirus-mediated gene transfer at birth. (1997) Journal of General Virology 78:3303-10.
C. Siegrist Vacciniation in the neonatal period and early infancy. Int. Rev Immunol. 19:195-219, 2000.
I. Belyakov. et al. Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses. Proc. Natl. Acad. Sci. USA 100:9458-63, 2003.
Zhu et al., Evaluation of Recombinant Vaccinia Virus—Measles Vaccines in Rhesus Macaques with Preexisting Measles Antibody, Virology 276:202-213, 2000.
Kovarik et al., Induction of Adult-like Antibody, Th1, and CTL Responses to Measles Hemagglutinin by Early Life Murine Immunization with an Attenuated Vaccinia-Derived NYVAC (KIL) Viral Vector, Virology 285:12-20, 2001.
Dadaglio et al., Efficient In Vivo Priming of Specific Cytotoxic T Cell Responses by Neonatal Dendritic Cells, J. Immmunology 168:2219-2224, 2002.
Ridge et al., Neonatal Tolerance Revisited: Turning on Newborn T Cells with Dendritic Cells, Science 271:1723-1726, 1996.
Antoine et al. The Complete Genomic Sequence of the Modified Vaccinia Ankara Strain: Comparison with Other Orthopoxviruses. Virology 1998; 244:365-396.
Wyatt et al. Priming and boosting immuni7to tespiratory syncytial virus by recombinant replication-defective vac
Chaplin Paul
Suter Mark
Vollstedt Sabine
Bavarian Nordic A/S
Law Office of Salvatore Arrigo
Mosher Mary E
Snyder Stuart W
LandOfFree
Modified vaccinia virus ankara for the vaccination of neonates does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modified vaccinia virus ankara for the vaccination of neonates, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modified vaccinia virus ankara for the vaccination of neonates will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2639770